Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

Author
:
HJ Gray
K Bell-McGuinn
GF Fleming
M Cristea
H Xiong
D Sullivan
Y Luo
MD McKee
W Munasinghe
LP Martin
Abstract
:

Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced ovarian cancer and other nonhematologic malignancies.
Year of Publication
:
2018
Journal
:
Gynecologic oncology
Date Published
:
2018
ISSN Number
:
0090-8258
URL
:
http://linkinghub.elsevier.com/retrieve/pii/S0090-8258(17)31620-7
DOI
:
10.1016/j.ygyno.2017.12.029
Short Title
:
Gynecol Oncol
Download citation